HERZLIYA, Israel and
NEW YORK, Nov. 29, 2011 /PRNewswire/ -- IMMUNE
Pharmaceuticals, an emerging leader in the development of antibody
based therapeutics for the treatment of inflammatory diseases and
cancer, today announced the appointment of Isaac Kobrin, M.D. to its Board of
Directors. Dr. Kobrin will play a key role in helping build
IMMUNE into a leading global biopharmaceutical company.
"We are thrilled and honored to welcome Isaac to the IMMUNE Board
of Directors," said Dr. Daniel
Teper, Founder, Chairman of the Board and Chief Executive
Officer of IMMUNE Pharmaceuticals. "Dr. Kobrin has an
exceptional track record in drug development and commercialization;
he is a true entrepreneur and company builder."
Dr. Kobrin led worldwide clinical programs from Phase I
development through to regulatory approval and marketing launch for
several major drugs. He spent 10 years at Roche Global
Headquarters in Basel, Switzerland
and in Nutley, New Jersey, USA.
He then joined Actelion Pharmaceuticals in September 1999 to build and lead its clinical
development department. Dr. Kobrin held the position of Head
of Clinical Development till 2009, when he was appointed to Chief
Medical Officer and Chairman of the Strategic and Portfolio
Board. At Actelion, Dr. Kobrin led the development of several
large programs, which supported a successful initial public
offering on the Swiss Stock Exchange Moreover, under Dr Kobrin's
leadership Tracleer, the flagship drug of Actelion reached
regulatory approval world-wide, which was the bases for Actelion's
growth to become the largest European-based global biotechnology
company.
Dr. Kobrin graduated from and completed his residency at
Hadassah Medical School in Jerusalem. He is Board certified
in Internal Medicine and completed a Fulbright Fellowship at the
Ochsner Foundation in New Orleans,
Louisiana, USA. Dr. Kobrin was a Senior Lecturer and
the Director of Pre Hypertension Research Unit at Mount Scopus
Hadassah Hospital prior to joining Roche in 1989.
"I am extremely proud to have been chosen as a member of the
Board of Directors of Immune Pharmaceuticals. I am very
impressed with the Company's research and development platforms
which include Bertilimumab, a first-in-class fully human monoclonal
antibody against eotaxin-1 ready to enter phase II in multiple
indications and the innovative Antibody Drug Conjugate technology
of NanoMabs that could significantly improve the efficacy and
safety of anti-cancer and anti-inflammatory drugs. Both
technologies could become meaningful therapeutic solutions and
result in long-term business success. I look forward to helping and
supporting Immune in their development and strategic plans together
with the other board members and the Management team," said Dr
Kobrin.
About IMMUNE Pharmaceuticals
IMMUNE Pharmaceuticals is an Israel and U.S. based biopharmaceutical
company focused on the development of next generation monoclonal
antibodies addressing significant unmet medical needs in the
treatment of inflammatory diseases and cancer. IMMUNE
Pharmaceuticals has built a robust pipeline of clinical and
pre-clinical candidates based on novel targets and best-in-class
antibody technologies. IMMUNE licensed worldwide rights for
systemic indications of Bertilimumab from iCo Therapeutics
(TSX:ICO) in June 2011, while iCo
retained rights to all ophthalmic indications. iCo originally
licensed the exclusive world-wide rights to Bertilimumab in 2006
from MedImmune Limited (formerly known as Cambridge Antibody
Technology Limited), the Global Biologics Arm of AstraZeneca.
IMMUNE also licensed from Yissum, the Technology Transfer Company
of Hebrew University of Jerusalem, an
Antibody Drug Conjugate platform (NanoMAbs), which allows to
deliver micro-doses of chemotherapeutics into target cells.
For more information, visit the Company website at:
www.immunepharmaceuticals.com
Forward Looking Statements
Certain statements included in this press release may be
considered forward-looking. Such statements involve known and
unknown risks, uncertainties and other factors that may cause
actual results, performance or achievements to be materially
different from those implied by such statements, and therefore
these statements should not be read as guarantees of future
performance or results. All forward-looking statements are based
IMMUNE Pharmaceuticals current beliefs as well as assumptions made
by and information currently available to IMMUNE Pharmaceuticals
and relate to, among other things, anticipated financial
performance, business prospects, strategies, regulatory
developments, market acceptance and future commitments. Readers are
cautioned not to place undue reliance on these forward-looking
statements, which speak only as of the date of this press release.
Due to risks and uncertainties; actual events may differ materially
from current expectations. IMMUNE Pharmaceuticals disclaims any
intention or obligation to update or revise any forward-looking
statements, whether as a result of new information, future events
or otherwise.
Contacts:
Mr. Serge Goldner, Chief Financial
Officer, IMMUNE Pharmaceuticals, +972505203100
serge.goldner@immunepharma.com
Ms Justyna Figiel, Media and
Investor Relations, IMMUNE Pharmaceuticals, 347-437-0218
justyna.figiel@immunepharma.com
Mrs. Marcy Nanus, Vice President,
The Trout Group, LLC., 646-378-2927,
mnanus@troutgroup.com
SOURCE IMMUNE Pharmaceuticals
